Compare · AZN vs GDTC
AZN vs GDTC
Side-by-side comparison of AstraZeneca PLC (AZN) and CytoMed Therapeutics Limited (GDTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GDTC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 23789.0x GDTC ($11.1M).
- AZN has hit the wire 13 times in the past 4 weeks while GDTC has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 0 for GDTC).
- Company
- AstraZeneca PLC
- CytoMed Therapeutics Limited
- Price
- -
- -
- Market cap
- $263.10B
- $11.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2023
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
Latest GDTC
- Amendment: Director Choo Chee Kong bought $300,000 worth of ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED (200,000 units at $1.50), increasing direct ownership by 46% to 630,324 units (SEC Form 4)
- SEC Form 4 filed by Director Choo Chee Kong
- SEC Form 6-K filed by CytoMed Therapeutics Limited
- Director Choo Chee Kong bought $128,778 worth of Ordinary Shares (112,000 units at $1.15), increasing direct ownership by 35% to 430,324 units (SEC Form 4)
- SEC Form 6-K filed by CytoMed Therapeutics Limited
- New insider Toh Keng Kiat claimed ownership of 4,000 units of Ordinary Shares (SEC Form 3)
- New insider Choo Chee Kong claimed ownership of 2,587,746 units of Ordinary Shares (SEC Form 3)
- New insider Yew Chak Hua claimed ownership of 2,469 units of Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Leong Mark Kei Wei
- New insider Goh Yvonne claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)